ScholarIQanswers from OpenAlex & ORCID
Philippe Szapary
ResearcherPublications, citations & collaboration network
Philippe Szapary is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Philippe Szapary have?
ScholarIQindexed works
Philippe Szapary has 88 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Philippe Szapary have?
ScholarIQcitation count
Philippe Szapary has 10,524 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Philippe Szapary?
ScholarIQh-index
Philippe Szapary has an h-index of 41 in OpenAlex.
What is the i10-index of Philippe Szapary?
ScholarIQi10-index
Philippe Szapary has an i10-index of 51 in OpenAlex.
What is the OpenAlex record for Philippe Szapary?
ScholarIQopenalex
The OpenAlex for Philippe Szapary is on the source record.
What are the most-cited papers on Philippe Szapary?
ScholarIQmost cited works
A Randomized Trial of a Low-Carbohydrate Diet for Obesity
Gary D. Foster, Holly R. Wyatt, James O. Hill, Brian G. McGuckin, Carrie Brill, B. Selma Mohammed, Philippe Szapary, Daniel J. Rader, Joel S. Edman, Samuel Klein
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
Bruce E. Sands, William J. Sandborn, Remo Panaccione, Christopher D. O’Brien, Hongyan Zhang, Jewel Johanns, Omoniyi J. Adedokun, Katherine Li, Laurent Peyrin‐Biroulet, Gert Van Assche, Silvio Danese, Stephan R. Targan, María T. Abreu, Tadakazu Hisamatsu, Philippe Szapary, Colleen Marano
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
Kim Papp, C.E.M. Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich, on behalf of the PHOENIX 1, PHOENIX 2 and ACCEPT Investigators
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen, Stacy Smith, Robert Matheson, Craig L. Leonardi, César A. Calderón, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J. Marciniak, Yasmine Wasfi, Yuhua Wang, Philippe Szapary, James G. Krueger